MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
15 Jul 2020
563
MedComm | Mitochondria as a target in cancer treatment
Scimea

Mitochondria are biosynthetic, bioenergetic, and signaling organelles existing in almost all eukaryotic cells, and their dysregulated function has been proved to be essential for tumorigenesis, tumor development, and tumor metastasis. Researchers from Tongji University Cancer Center provided an overview concerning the role mitochondria plays in cancer treatment and its potentiality to be a target in cancer treatment.


1600073762(1).png


The importance of mitochondria in cancer had been ignored for a long time. Around 100 years ago, Otto Warburg discovered that cancer cells undergo aerobic glycolysis even in the presence of oxygen, which was later reasoned that cancer might arise from impaired mitochondria. So far, the importance of mitochondria in cancer has been proved experimentally in many ways. Recent findings also suggests that mitochondria not only play an important role in cancer cell viability but also might be essential for tumorigenesis. Thus, there is a urgent interest in pursuing study of mitochondria biology in cancers and targeting this organelle therapeutically (Table 1).

 

1600137882(1).jpg

Table 1  Reagents targeting mitochondria for cancer therapy


In addition, the authors came up with a current view that mitochondria play a pivotal role in tumor cells; how tumor cells rewind mitochondrial function for their oncogenic purpose via known or unknown mechanisms by key oncogenes or tumor suppressors then the authors went through reagents and strategies currently available targeting mitochondria when treating tumors. Recently, merging data suggest that slow cycling cancer cells/cancer stem cells have distinctive mitochondrial metabolism comparing to bulk tumor cells and mitochondria inhibitors seem to be promising to target them, which are resistant to traditional radio and chemotherapies. Thus the role of mitochondria in these cancer stem cells was disscussed and evidence of mitochondria as a target from different aspects was summerized.



Article Access: https://onlinelibrary.wiley.com/doi/10.1002/mco2.16

 

 

                                                                                                                              

Website for MedComm: https://onlinelibrary.wiley.com/journal/26882663

Looking forward to your contributions.


Vice President Chen Mao Was Selected as a Leading Talent in Science and Technology Innovation in the National “10,000-Talent Program”
Notice: James Naismith, the first director of the Rosalind Franklin Institute in the UK Gives a Speech in Sichuan University
Guangdong Critical Care Team Visit to West China Hospital to Conduct "Dialogue on ICU – Trip to West China Hospital" Exchange Visit
MedComm | Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China
Recap of 2019 China-Japan Advanced Medical and New Drug R&D Summit and Achievements Transformation Conference Available Now!
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1